rss
Br J Ophthalmol doi:10.1136/bjo.2007.127910

A new advanced glycation inhibitor LR-90 prevents experimental diabetic retinopathy in rats

  1. Ashay D Bhatwadekar (abhatwadekar01{at}qub.ac.uk),
  2. Josephine V Glenn (j.v.glenn{at}qub.ac.uk),
  3. James L Figarola (jlfigarola{at}coh.org),
  4. Stephen Scott (sscott{at}coh.org),
  5. Tom A Gardiner (t.gardiner{at}qub.ac.uk),
  6. Samuel Rahbar (srahbar{at}coh.org),
  7. Alan W Stitt (a.stitt{at}qub.ac.uk)
  1. Queen's University Belfast, United Kingdom
  2. Queen' S University Belfast, United Kingdom
  3. City of Hope National Medical Centre, United States
  4. City of Hope National Medical Centre, United States
  5. Queens University-Belfast, United Kingdom
  6. City of Hope National Medical Center and Beckman Research Institute,, United States
  7. The Queen's University of Belfast, United Kingdom
    • Published Online First 22 January 2008

    Abstract

    Background/Aims: Diabetic retinopathy is associated with accumulation of advanced glycation end products (AGEs) in the retinal microvasculature. LR-90 is an effective multistage inhibitor of advanced glycation with renoprotective and anti-inflammatory properties. In the present study we have explored the role of LR-90 in the progression of experimental diabetic retinopathy.

    Methods: Streptozotocin (STZ) induced diabetic Sprague-Dawley rats were treated with LR-90 (50mg/l in drinking water) for up to 32 weeks. At the end of the study eyes were enucleated and subjected to trypsin digestion and staining with light green-haematoxylin. Acellular capillaries and number of pericytes were quantified in random fields using light microscopy.

    Results: In the LR-90 treated diabetic animals, acellular capillary numbers were reduced to 1.63 ± 0.20 from 2.58 ± 0.49 (p<0.05) in diabetic controls. Also, LR-90 treatment significantly restored pericyte deficit from 18.12 ± 0.98 in diabetic rats to 24.19 ± 0.76 (p<0.001) in the LR-90 treated group. Conclusion: These findings demonstrate that LR-90 can effectively inhibit important lesions of diabetic retinopathy. This agent has potential for preventing retinopathy in diabetic patients.

    This Article

    1. Abstract
    2. PDF
    3. All Versions of this Article:
      1. bjo.2007.127910v1
      2. 92/4/545 most recent

    Responses

    1. Submit a response
    2. No responses published

    Social bookmarking

    Register for free content


    Free sample
     This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
    View free sample issue >>

    Free archive
    The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
    Register to access the free archive >>

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.